TY - JOUR
AU - Beckman, Joshua A.
AB - Review: Clinical Cardiology: New Frontiers Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I Mark A. Creager, MD; Thomas F. Lüscher, MD, FRCP; and prepared with the assistance of Francesco Cosentino, MD, PhD; Joshua A. Beckman, MD iabetes mellitus affects approximately 100 million per- cells. In addition, NO protects the blood vessel from endog- D sons worldwide. Five to ten percent have type 1 enous injury—ie, atherosclerosis— by mediating molecular (formerly known as insulin-dependent) and 90% to 95% have signals that prevent platelet and leukocyte interaction with the type 2 (non–insulin-dependent) diabetes mellitus. It is likely vascular wall and inhibit vascular smooth muscle cell prolif- 5–7 that the incidence of type 2 diabetes will rise as a conse- eration and migration. Conversely, the loss of endotheli- quence of lifestyle patterns contributing to obesity. Cardio- um-derived NO permits increased activity of the proinflam- vascular physicians are encountering many of these patients matory transcription factor nuclear factor kappa B (NF-

), because vascular diseases are the principal causes of death resulting in expression of leukocyte adhesion molecules and and disability in people with diabetes. The macrovascular production of chemokines and cytokines. These actions manifestations include atherosclerosis and medial calcifica- 
TI - Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I
JF - Circulation
DO - 10.1161/01.CIR.0000091257.27563.32
DA - 2003-09-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/diabetes-and-vascular-disease-pathophysiology-clinical-consequences-61dzHnhC6t
SP - 1527
EP - 1532
VL - 108
IS - 12
DP - DeepDyve
ER -